08:33 AM EST, 11/05/2025 (MT Newswires) -- Praxis Precision Medicines ( PRAX ) reported a Q3 net loss Wednesday of $3.36 per diluted share, widening from a loss of $2.75 a year earlier.

Analysts polled by FactSet expected a loss of $3.36.

The company said it did not recognize any collaboration revenue in the quarter ended Sept. 30, compared with $302,000 a year earlier.

Analysts surveyed by FactSet expected $100,000.

As of Sept. 30, the company said it had $389.2 million in cash, cash equivalents and marketable securities, which, together with net proceeds from an October public offering of $567 million, are expected to fund operations into 2028.